UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 11.

Gramatzki, D; Weller, M (2016). Reply to glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009. Cancer, 122(23):3740-3741.

Silginer, M; Burghardt, I; Gramatzki, D; Bunse, L; Leske, H; Rushing, E J; Hao, N; Platten, M; Weller, M; Roth, P (2016). The aryl hydrocarbon receptor links integrin signaling to the TGF-β pathway. Oncogene, 35(25):3260-3271.

Weller, Michael; Weber, Ruthild G; Willscher, Edith; Riehmer, Vera; Hentschel, Bettina; Kreuz, Markus; Felsberg, Jörg; Beyer, Ulrike; Löffler-Wirth, Henry; Kaulich, Kerstin; Steinbach, Joachim P; Hartmann, Christian; Gramatzki, D; Schramm, J; Westphal, M; Schackert, G; Simon, M; Martens, T; Boström, J; Hagel, C; Sabel, M; Krex, D; Tonn, J C; Wick, W; Noell, S; Schlegel, U; Radlwimmer, B; Pietsch, T; Loeffler, M; von Deimling, A; Binder, H; Reifenberger, G (2015). Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathologica, 129(5):679-693.

Frei, K; Gramatzki, D; Tritschler, I; Schroeder, J J; Espinoza, L; Rushing, E J; Weller, M (2015). Transforming growth factor-β pathway activity in glioblastoma. OncoTarget, 6(8):5963-5977.

Weller, M; Kaulich, K; Hentschel, B; Felsberg, J; Gramatzki, D; Pietsch, T; Simon, M; Westphal, M; Schackert, G; Tonn, J C; von Deimling, A; Davis, T; Weiss, W A; Loeffler, M; Reifenberger, G (2014). Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. International Journal of Cancer, 134(10):2437-2447.

Reifenberger, G; Weber, R G; Riehmer, V; Kaulich, K; Willscher, E; Wirth, H; Gietzelt, J; Hentschel, B; Westphal, M; Simon, M; Schackert, G; Schramm, J; Matschke, J; Sabel, M C; Gramatzki, D; Felsberg, J; Hartmann, C; Steinbach, J P; Schlegel, U; Wick, W; Radlwimmer, B; Pietsch, T; Tonn, J C; von Deimling, A; Binder, H; Weller, M; Loeffler, M (2014). Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. International Journal of Cancer, 135(8):1822-1831.

Blaes, J; Weiler, M; Sahm, F; Hentschel, B; Osswald, M; Czabanka, M; Thomé, C M; Schliesser, M G; Pusch, S; Luger, S; Winkler, F; Radbruch, A; Jugold, M; Simon, M; Steinbach, J P; Schackert, G; Tatagiba, M; Westphal, M; Tonn, J C; Gramatzki, D; Pietsch, T; Hartmann, C; Glimm, H; Vajkoczy, P; von Deimling, A; Platten, M; Weller, M; Wick, W (2014). NDRG1 prognosticates the natural course of disease in WHO grade II glioma. Journal of Neuro-Oncology, 117(1):25-32.

Gramatzki, D; Herrmann, C; Happold, C; Becker, K A; Gulbins, E; Weller, M; Tabatabai, G (2013). Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway. PLoS ONE, 8(5):e63527.

Wick, W; Meisner, C; Hentschel, B; Platten, M; Schilling, A; Wiestler, B; Sabel, M C; Koeppen, S; Ketter, R; Weiler, M; Tabatabai, G; von Deimling, A; Gramatzki, D; Westphal, M; Schackert, G; Loeffler, M; Simon, M; Reifenberger, G; Weller, M (2013). Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology, 81(17):1515-1522.

Gramatzki, D; Pantazis, G; Schittenhelm, J; Tabatabai, G; Köhle, C; Wick, W; Schwarz, M; Weller, M; Tritschler, I (2009). Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells. Oncogene, 28(28):2593-2605.

Tritschler, I; Gramatzki, D; Capper, D; Mittelbronn, M; Meyermann, R; Saharinen, J; Wick, W; Keski-Oja, J; Weller, M (2009). Modulation of TGF-beta activity by latent TGF-beta-binding protein 1 in human malignant glioma cells. International Journal of Cancer, 125(3):530-540.

This list was generated on Tue Jul 25 04:48:53 2017 CEST.